FUSE — Foundry for Urologic Science and Entrepreneurship

Clinical Excellence ● Entrepreneurial Thinking ● European Impact

FUSE

Foundry for Urologic Science & Entrepreneurship

We are building a world-class innovation hub where excellence in medical research meets entrepreneurship. By bringing together top-tier clinicians, researchers, entrepreneurs, investors, and industry partners, we transform scientific discoveries into real-world impact — accelerating the development of new technologies, therapies, companies, and models of care that improve patients' lives.

Discover the Model Talk to Us

What We Build

Two tracks. One mission. One legal structure.

FUSE runs two distinct innovation tracks under one roof, sharing one overarching mission: Clinical Excellence.

Permanent Foundation — Data Platform

FUSE's primary competitive advantage is its unprecedented patient volume. FUSE operationalizes that advantage through a structured, anonymized, CNIL-compliant data infrastructure — built before either track launches, and maintained with rigour every day.

Track One — From Year 1

Open Innovation

A Curation Model — The Accelerator

The idea originates outside. We accelerate it.

We select existing founder-led teams with proven ideas and accelerate their development — rigorously, inside a real hospital environment. The accelerator selects, funds, provides data and clinical access, and mentors.

Selection · Capital · Clinical Access · Mentorship

Track Two — Once Track 1 Is Stable

Foundry

A Creation Model — The Venture Studio

The idea originates inside. We are co-founder and builder.

We originate ideas internally, recruit talent to execute them, and build companies from scratch. The studio is co-founder, builder, and funder — with IP ownership from day one.

Idea Generation · Talent · IP Ownership · Co-Building

"In the coming years, artificial intelligence will be the main driver of innovation in healthcare. It will be the key to major advances in medical diagnosis, prevention, and treatment, as well as in the organization of care."

Prof. Michaël Peyromaure — Head of Urology, AP-HP Hôpital Cochin · Medical Director, Uroplus Foundation

Why FUSE

A Unique European Value Proposition

The department of Urology at the AP-HP Cochin Hospital, under the direction of Pr. Michaël Peyromaure, possesses several key assets that together create a strong foundation for innovation in HealthTech: exceptional patient volume, structured access to clinical data, and leadership that recognizes both the importance of innovation and the transformative potential of Artificial Intelligence. Combined with an already existing foundation dedicated to urology — which brings private funding and a key degree of operational independence — this creates, in our view, a uniquely favorable environment within European urology to build a long-term and credible HealthTech innovation platform, inspired by the operational principles of leading Silicon Valley accelerators that some of our founding team members have experienced firsthand.

Clinical Volume as Infrastructure

Innovation in healthcare depends on proximity to patients, high-quality clinical expertise, and real-world evidence. FUSE brings these elements together, creating a unique environment for developing, validating, and scaling solutions that can improve patient care.

Disease-Area Focus

FUSE is not a generalist program. Every startup selected, every pilot run, every dataset accessed is anchored in focused verticals. Each cohort focuses on one or two thematic areas, ensuring clinical relevance and cohort coherence — and attracting world-class founders and researchers.

Dual-Track Architecture

No European health institution has combined an accelerator and a venture studio in a single legal structure in HealthTech. Track 1 builds reputation and deal flow. Track 2 builds IP and deep long-term value. Together, they create a flywheel no single-model competitor can match.

Private. Independent. Focused.

FUSE operates as an independent SAS subsidiary — with its own governance, designed to reach operational break-even. Free from the procurement cycles and political constraints of public institutions, it moves at the speed innovation demands.

The Team

People you can bet on.

Clinical authority. Entrepreneurial track record. Legal rigour. Statistical depth and AI authority. Each co-founder brings a dimension that is rare on its own — together, they cover every axis a HealthTech innovation engine requires.

Prof. Michaël Peyromaure

Medical Director & Co-Founder

Head of Urology, AP-HP Hôpital Cochin — Paris Medical Director, Uroplus Foundation Leading French urologist in prostate cancer Exceptional patient volume & clinical access

Profile

Erwan Lepennec

Scientific Advisor & Co-Founder

Professor, École Polytechnique — Applied Mathematics Head of CMAP Head of MScT Data Science & AI, Polytechnique Executive Education Co-Founder Sonio — Exit to Samsung $92M (2025) Co-Founder Let it Wave — Exit (2008) ENS Cachan — DEA · Agrégation · MVA

Bruno Derieux

Legal Counsel & Co-Founder

Head of Corporate / M&A — Linklaters Paris One of the world's leading law firms Deal structuring & governance expertise Complex innovation engine legal architecture

Profile

Olivier Carteret

CEO & Co-Founder

Founder & CEO Aristeia — Founded 2001, exit 2016 Portfolio Founder Former Olympic Athlete UC Berkeley Haas — MBA ESCP Europe — Master's (Grandes Écoles)

Advisory Board

Hélène Mathieu

Health Innovation Networks

Resonance Health Europe — Cross-border health innovation network. Deep expertise in European health ecosystems and international partnership development.

Prof. Laurent Lantieri

Surgical Excellence & Medical Innovation

University Professor and Chief of Plastic Reconstructive Surgery, Hôpital Européen Georges Pompidou. One of France's most distinguished surgeons, bringing clinical prestige and an innovation mindset.

Investment Thesis

A strategic infrastructure investment.

"We have the patients, the data, the space, and the top-tier medical specialists. What we build now is the engine that turns these assets into Europe's most important innovation platform in prostate cancer — and possibly in HealthTech."

Olivier Carteret — CEO, FUSE

The Question Is Not IRR

The right question is: what does it cost to become the leading European institution in HealthTech innovation — and what is that position worth? The answer reframes what investment means.

Financial Returns Are Real

At 4 companies per cohort and 1 cohort per year, total program investment over 5 years is approximately €7M. A single exit at €500M valuation on a 7% stake returns €35M. Returns are possible. They are not the primary objective.

Strategic Value Is Permanent

Recognition as Europe's leading urology institution. Philanthropic and EU grant leverage. Corporate partnerships at premium terms. A proprietary data asset that compounds with every cohort. These do not appear on a cap table — but they are durable.